Skip to main content

Research Repository

Advanced Search

All Outputs (20)

Current Use of EEN in Pre-Operative Optimisation in Crohn’s Disease (2021)
Journal Article
Shariff, S., Moran, G., Grimes, C., & Cooney, R. M. (2021). Current Use of EEN in Pre-Operative Optimisation in Crohn’s Disease. Nutrients, 13(12), Article 4389. https://doi.org/10.3390/nu13124389

Despite the increasing array of medications available for the treatment of Crohn’s disease and a focus on mucosal healing, approximately 35% of patients with Crohn’s disease undergo bowel surgery at some stage. The importance of nutritional optimisat... Read More about Current Use of EEN in Pre-Operative Optimisation in Crohn’s Disease.

Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline (2021)
Journal Article
Fox, C. P., Ahearne, M. J., Pettengell, R., Dearden, C., El-Sharkawi, D., Kassam, S., …Collins, G. (2022). Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline. British Journal of Haematology, 196(3), 507-522. https://doi.org/10.1111/bjh.17951

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial (2021)
Journal Article
Fox, C. P., Ali, A. S., McIlroy, G., Thust, S., Martinez-Calle, N., Jackson, A. E., …Cwynarski, K. (2021). A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. Blood Advances, 5(20), 4073-4082. https://doi.org/10.1182/bloodadvances.2021004779

Relapsed or refractory primary central nervous system lymphoma (rrPCNSL) confers a poor prognosis with no accepted standard of care. Very few prospective studies have been conducted in this patient group. This study was a multicenter phase 1/2 study... Read More about A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.

Translational Analysis of Moderate to Severe Asthma GWAS Signals Into Candidate Causal Genes and Their Functional, Tissue-Dependent and Disease-Related Associations (2021)
Journal Article
Portelli, M. A., Rakkar, K., Hu, S., Guo, Y., Adcock, I. M., & Sayers, I. (2021). Translational Analysis of Moderate to Severe Asthma GWAS Signals Into Candidate Causal Genes and Their Functional, Tissue-Dependent and Disease-Related Associations. Frontiers in Allergy, 2, Article 738741. https://doi.org/10.3389/falgy.2021.738741

Asthma affects more than 300 million people globally and is both under diagnosed and under treated. The most recent and largest genome-wide association study investigating moderate to severe asthma to date was carried out in 2019 and identified 25 in... Read More about Translational Analysis of Moderate to Severe Asthma GWAS Signals Into Candidate Causal Genes and Their Functional, Tissue-Dependent and Disease-Related Associations.

Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England (2021)
Journal Article
Hounsome, L., Eyre, T. A., Ireland, R., Hodson, A., Walewska, R., Ardeshna, K., …Fields, P. A. (2022). Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England. British Journal of Cancer, 126(1), 134-143. https://doi.org/10.1038/s41416-021-01525-4

Background: We wished to examine treatment and outcome patterns in older diffuse large B-cell lymphoma (DLBCL) patients, with a focus on the effect of route-to-diagnosis to outcome. Methods: Data were extracted from Public Health England’s National C... Read More about Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England.

United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia (2021)
Journal Article
Wauters, L., Dickman, R., Drug, V., Mulak, A., Serra, J., Enck, P., …Zerbib, F. (2021). United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. Neurogastroenterology and Motility, 33(9), Article e14238. https://doi.org/10.1111/nmo.14238

Background Functional dyspepsia (FD) is one of the most common conditions in clinical practice. In spite of its prevalence, FD is associated with major uncertainties in terms of its definition, underlying pathophysiology, diagnosis, treatment, and p... Read More about United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia.

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma (2021)
Journal Article
Maloney, D. G., Kuruvilla, J., Liu, F. F., Kostic, A., Kim, Y., Bonner, A., …Cartron, G. (2021). Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. Journal of Hematology and Oncology, 14(1), Article 140. https://doi.org/10.1186/s13045-021-01144-9

Background: In the absence of randomized studies directly comparing chimeric antigen receptor T cell therapies, this study used matching-adjusted indirect comparisons (MAIC) to evaluate the comparative efficacy and safety of lisocabtagene maraleucel... Read More about Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.

Developing good practice by understanding how UK medical schools address low level concerns: a survey study (2021)
Journal Article
Vivekananda-Schmidt, P., Bolton, C., & Knox, R. (2022). Developing good practice by understanding how UK medical schools address low level concerns: a survey study. Education for Primary Care, 33(1), 6-12. https://doi.org/10.1080/14739879.2021.1948805

In the literature, a distinction is made between low-level concerns and what is regarded as fitness to practise concerns. The General Medical Council expects all UK medical schools to have a transparent process in place about how concerns about its m... Read More about Developing good practice by understanding how UK medical schools address low level concerns: a survey study.

Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study (2021)
Journal Article
Wilmot, E. G., Close, K. L., Jurišić‐Eržen, D., Bruttomesso, D., Ampudia‐Blasco, F. J., Bosnyak, Z., …Seufert, J. (2021). Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study. Diabetes, Obesity and Metabolism, 23(8), 1892-1901. https://doi.org/10.1111/dom.14416

Aims To conduct a secondary analysis of the SAGE study to evaluate the association between glycaemic control and patient-reported outcomes (PROs), in adults with type 1 diabetes (T1DM) across different age groups and regions. Materials and metho... Read More about Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study.

Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort (2021)
Journal Article
Martinez-Calle, N., Kirkwood, A. A., Lamb, M., Smith, A., Khwaja, J., Manos, K., …Fox, C. P. (2021). Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy, 38(7), 3789-3802. https://doi.org/10.1007/s12325-021-01764-0

Introduction: Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine... Read More about Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.

Characterisation of dysplastic liver nodules using low-pass DNA sequencing and detection of chromosome arm-level abnormalities in blood-derived cell-free DNA (2021)
Journal Article
Fateen, W., Johnson, P. J., Wood, H. M., Zhang, H., He, S., El-Meteini, M., …Quirke, P. (2021). Characterisation of dysplastic liver nodules using low-pass DNA sequencing and detection of chromosome arm-level abnormalities in blood-derived cell-free DNA. Journal of Pathology, 255(1), 30-40. https://doi.org/10.1002/path.5734

High grade dysplasia carries significant risk of transformation to hepatocellular carcinoma (HCC). Despite this, at the current standard of care, all non-malignant hepatic nodules including high grade dysplastic nodules are managed similarly. This is... Read More about Characterisation of dysplastic liver nodules using low-pass DNA sequencing and detection of chromosome arm-level abnormalities in blood-derived cell-free DNA.

Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH) (2021)
Journal Article
Gordon, V. M., Adhikary, R., Aithal, G. P., Appleby, V., Das, D., Day, J., …Gleeson, D. (2022). Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH). Frontline Gastroenterology, 13(2), 126-132. https://doi.org/10.1136/flgastro-2020-101661

Background Autoimmune hepatitis (AIH) is a substantial UK health burden, but there is variation in care, facilities and in opinion regarding management. We conducted an audit of service provision and care of patients with AIH in 28 UK hospitals. Meth... Read More about Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH).

Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) (2021)
Journal Article
Barajas, R. F., Politi, L. S., Anzalone, N., Schöder, H., Fox, C. P., Boxerman, J. L., …Hu, L. S. (2021). Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-Oncology, 23(7), 1056-1071. https://doi.org/10.1093/neuonc/noab020

Advanced molecular and pathophysiologic characterization of primary central nervous system lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, staging, an... Read More about Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).

Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients — A British Society for Haematology Guideline (2021)
Journal Article
Shah, N., Eyre, T. A., Tucker, D., Kassam, S., Parmar, J., Featherstone, C., …Haemato‐Oncology Task Force of the British Society for Haematology and the British Transplantation Society. (2021). Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients — A British Society for Haematology Guideline. British Journal of Haematology, 193(4), 727-740. https://doi.org/10.1111/bjh.17421

Improving lung health in low-income and middle-income countries: from challenges to solutions (2021)
Journal Article
Meghji, J., Mortimer, K., Agusti, A., Allwood, B. W., Asher, I., Bateman, E. D., …Marks, G. B. (2021). Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, 397(10277), 928-940. https://doi.org/10.1016/S0140-6736%2821%2900458-X

Low-income and middle-income countries (LMICs) bear a disproportionately high burden of the global morbidity and mortality caused by chronic respiratory diseases (CRDs), including asthma, chronic obstructive pulmonary disease, bronchiectasis, and pos... Read More about Improving lung health in low-income and middle-income countries: from challenges to solutions.

Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study (2021)
Journal Article
Sebastian, S., Walker, G. J., Kennedy, N. A., Conley, T. E., Patel, K. V., Subramanian, S., …Zafar, M. (2021). Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterology and Hepatology, 6(4), 271-281. https://doi.org/10.1016/s2468-1253%2821%2900016-9

Background There is a paucity of evidence to support safe and effective management of patients with acute severe ulcerative colitis during the COVID-19 pandemic. We sought to identify alterations to established conventional evidence-based management... Read More about Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.

ERS international congress 2020: Highlights from the paediatric assembly (2021)
Journal Article
Ardura-Garcia, C., Cuevas-Ocaña, S., Freitag, N., Kampouras, A., King, J. A., Kouis, P., …Pijnenburg, M. W. (2021). ERS international congress 2020: Highlights from the paediatric assembly. ERJ Open Research, 7(1), Article 00893-2020. https://doi.org/10.1183/23120541.00893-2020

In this review, the Paediatric Assembly of the European Respiratory Society (ERS) presents a summary of the highlights and most relevant findings in the field of paediatric respiratory medicine presented at the virtual ERS International Congress 2020... Read More about ERS international congress 2020: Highlights from the paediatric assembly.

A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies (2021)
Journal Article
Collins, G. P., Clevenger, T. N., Burke, K. A., Yang, B., MacDonald, A., Cunningham, D., …Flinn, I. (2021). A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. Leukemia & Lymphoma, 62(11), 2625-2636. https://doi.org/10.1080/10428194.2021.1938027

In a phase 1b study of acalabrutinib (a covalent Bruton tyrosine kinase (BTK) inhibitor) in combination with vistusertib (a dual mTORC1/2 inhibitor) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), multiple ascending doses... Read More about A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.